JP6611710B2 - 脳損傷の検出および転帰についてのマルチプロテインバイオマーカー測定法 - Google Patents

脳損傷の検出および転帰についてのマルチプロテインバイオマーカー測定法 Download PDF

Info

Publication number
JP6611710B2
JP6611710B2 JP2016527092A JP2016527092A JP6611710B2 JP 6611710 B2 JP6611710 B2 JP 6611710B2 JP 2016527092 A JP2016527092 A JP 2016527092A JP 2016527092 A JP2016527092 A JP 2016527092A JP 6611710 B2 JP6611710 B2 JP 6611710B2
Authority
JP
Japan
Prior art keywords
biomarker
tbi
bdnf
level
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016527092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016533499A5 (enExample
JP2016533499A (ja
Inventor
アレン ディー エヴェレット
エイク ジェニファー イー ヴァン
フレッド コーリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2016533499A publication Critical patent/JP2016533499A/ja
Publication of JP2016533499A5 publication Critical patent/JP2016533499A5/ja
Priority to JP2019195925A priority Critical patent/JP6980291B2/ja
Application granted granted Critical
Publication of JP6611710B2 publication Critical patent/JP6611710B2/ja
Priority to JP2021181686A priority patent/JP2022023999A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/825—Metallothioneins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
JP2016527092A 2013-07-17 2014-07-17 脳損傷の検出および転帰についてのマルチプロテインバイオマーカー測定法 Active JP6611710B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019195925A JP6980291B2 (ja) 2013-07-17 2019-10-29 脳損傷の診断／予後判定／評価において有用な組成物及びキット
JP2021181686A JP2022023999A (ja) 2013-07-17 2021-11-08 脳損傷の予測方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361847213P 2013-07-17 2013-07-17
US61/847,213 2013-07-17
PCT/US2014/046986 WO2015009907A1 (en) 2013-07-17 2014-07-17 A multi-protein biomarker assay for brain injury detection and outcome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019195925A Division JP6980291B2 (ja) 2013-07-17 2019-10-29 脳損傷の診断／予後判定／評価において有用な組成物及びキット

Publications (3)

Publication Number Publication Date
JP2016533499A JP2016533499A (ja) 2016-10-27
JP2016533499A5 JP2016533499A5 (enExample) 2017-08-24
JP6611710B2 true JP6611710B2 (ja) 2019-11-27

Family

ID=52346714

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016527092A Active JP6611710B2 (ja) 2013-07-17 2014-07-17 脳損傷の検出および転帰についてのマルチプロテインバイオマーカー測定法
JP2019195925A Active JP6980291B2 (ja) 2013-07-17 2019-10-29 脳損傷の診断／予後判定／評価において有用な組成物及びキット
JP2021181686A Pending JP2022023999A (ja) 2013-07-17 2021-11-08 脳損傷の予測方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019195925A Active JP6980291B2 (ja) 2013-07-17 2019-10-29 脳損傷の診断／予後判定／評価において有用な組成物及びキット
JP2021181686A Pending JP2022023999A (ja) 2013-07-17 2021-11-08 脳損傷の予測方法

Country Status (5)

Country Link
US (3) US10534003B2 (enExample)
EP (2) EP3022322A4 (enExample)
JP (3) JP6611710B2 (enExample)
IL (1) IL243393A0 (enExample)
WO (1) WO2015009907A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12172017B2 (en) * 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US9709573B2 (en) * 2012-03-13 2017-07-18 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
EP3022322A4 (en) 2013-07-17 2017-05-17 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
EP3254106A4 (en) 2015-02-05 2018-10-03 Immunarray USA, Inc. Methods and compositions for diagnosing brain injury or neurodegeneration
US10667737B2 (en) 2015-03-23 2020-06-02 International Business Machines Corporation Monitoring a person for indications of a brain injury
FI20155280A7 (fi) 2015-04-15 2016-10-16 Medicortex Finland Oy Aivovamman prognostisia ja diagnostisia glykaanipohjaisia biomarkkereita
US10244971B2 (en) * 2015-05-12 2019-04-02 International Business Machines Corporation Mouthguard for analysis of biomarkers for traumatic brain injury
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
WO2017127756A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Control of vagal stimulation
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US20180106818A1 (en) * 2016-10-03 2018-04-19 Abbott Laboratories Methods of assessing gfap status in patient samples
US12020820B1 (en) 2017-03-03 2024-06-25 Cerner Innovation, Inc. Predicting sphingolipidoses (fabry's disease) and decision support
US11335461B1 (en) * 2017-03-06 2022-05-17 Cerner Innovation, Inc. Predicting glycogen storage diseases (Pompe disease) and decision support
WO2018175942A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
EP3610268B1 (en) 2017-04-15 2025-09-24 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
BR112019022476A2 (pt) 2017-04-28 2020-05-12 Abbott Laboratories Métodos para o auxílio no diagnóstico e determinação hiperagudos de lesão cerebral traumática usando biomarcadores iniciais em pelo menos duas amostras a partir do mesmo ser humano
US11709168B2 (en) 2017-05-23 2023-07-25 Brainbox Solutions, Inc. Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
WO2018218169A1 (en) * 2017-05-25 2018-11-29 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
CA3059607A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i
JP7454945B2 (ja) 2017-07-03 2024-03-25 アボット・ラボラトリーズ 血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
KR102690820B1 (ko) * 2017-07-14 2024-08-02 가부시키가이샤 엠씨비아이 질환 검출 방법
EP3668402B1 (en) 2017-08-14 2024-07-31 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
KR102633621B1 (ko) * 2017-09-01 2024-02-05 벤 바이오사이언시스 코포레이션 진단 및 치료 모니터링용 바이오마커로서의 당펩티드의 식별 및 용도
US11923048B1 (en) 2017-10-03 2024-03-05 Cerner Innovation, Inc. Determining mucopolysaccharidoses and decision support tool
CA3067055A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
BR112019028254A2 (pt) 2017-12-09 2020-07-14 Abbott Laboratories métodos para ajudar no diagnóstico e avaliação de um paciente que sofreu uma lesão ortopédica e que sofreu ou pode ter sofrido uma lesão na cabeça, tal como uma lesão cerebral traumática (lct) leve, usando a proteína ácida fibrilar glial (gfap) e/ou a hidrolase carbóxi-terminal da ubiquitina l1 (uch-l1)
EP3732489B1 (en) * 2017-12-29 2025-10-22 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
WO2020006445A1 (en) 2018-06-29 2020-01-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomarkers and treatment methods for traumatic brain injury associated impairments
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
CA3128367A1 (en) * 2019-02-01 2020-08-06 Venn Biosciences Corporation Biomarkers for diagnosing ovarian cancer
EP3952982B1 (en) 2019-04-12 2024-03-27 Setpoint Medical Corporation Vagus nerve stimulation system to treat neurodegenerative disorders
WO2020223462A1 (en) * 2019-04-30 2020-11-05 University Of Florida Research Foundation, Inc. Biomarker panel for sepsis encephalopathy
KR102464243B1 (ko) * 2020-04-01 2022-11-08 프리시젼바이오 주식회사 외상성 뇌손상 바이오마커 검출용 시분해 형광분석 측방유동 분석장치 및 이를 이용한 외상성 뇌손상 바이오마커 측정방법
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
EP3982123A1 (en) * 2020-10-08 2022-04-13 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Markers and their use in brain injury
KR102189144B1 (ko) * 2020-10-15 2020-12-09 서울대학교병원 만성신장질환 악화 예측 마커 및 이를 이용한 악화 예측 방법
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
FI130340B (en) * 2022-02-22 2023-06-29 Medicortex Finland Oy Procedure for the diagnosis of traumatic brain injury
CN114594273B (zh) * 2022-05-09 2024-02-27 上海众启生物科技有限公司 一种脑梗塞生物标记物及其应用
CA3258179A1 (en) * 2022-06-05 2023-12-14 Sportgait Inc HEALTHCARE SYSTEM AND METHODS FOR MANAGING BRAIN INJURIES OR COMMOTIONS
JP7489723B2 (ja) 2022-10-05 2024-05-24 和哉 松尾 プログラム、情報処理装置、情報処理方法、および学習モデルの生成方法
WO2025188805A1 (en) * 2024-03-04 2025-09-12 University Of Denver Blood based rapid diagnostic system for brain hemorrhage detection and associated methods

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
SE462454B (sv) 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
ATE160821T1 (de) 1990-06-11 1997-12-15 Nexstar Pharmaceuticals Inc Nukleinsäureliganden
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
NZ267842A (en) 1993-05-28 1997-09-22 Baylor College Medicine Apparatus for measuring molecular mass (by mass spectrometry) in which the sample is ionised on the sample holder and desorbed therefrom by laser pulses
US5866434A (en) 1994-12-08 1999-02-02 Meso Scale Technology Graphitic nanotubes in luminescence assays
US6207369B1 (en) 1995-03-10 2001-03-27 Meso Scale Technologies, Llc Multi-array, multi-specific electrochemiluminescence testing
US6140045A (en) 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
BR9607193B1 (pt) 1995-03-10 2009-01-13 teste de eletroquimioluscÊncia multi-especÍfico de méltiplos conjuntos.
US6673533B1 (en) 1995-03-10 2004-01-06 Meso Scale Technologies, Llc. Multi-array multi-specific electrochemiluminescence testing
US6319670B1 (en) 1995-05-09 2001-11-20 Meso Scale Technology Llp Methods and apparatus for improved luminescence assays using microparticles
JP2000502450A (ja) 1995-12-22 2000-02-29 アボツト・ラボラトリーズ 蛍光偏光免疫アッセイによる診断法
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6413783B1 (en) 1997-09-18 2002-07-02 Meso Scale Technologies, Llc Assay sonication apparatus and methodology
CA2323638A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6780606B1 (en) 1999-02-26 2004-08-24 Synx Pharma, Inc. Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
WO2000056934A1 (en) 1999-03-24 2000-09-28 Packard Bioscience Company Continuous porous matrix arrays
EP1236173A2 (en) 1999-10-27 2002-09-04 Biowulf Technologies, LLC Methods and devices for identifying patterns in biological systems
SG144731A1 (en) 2000-07-18 2008-08-28 Correlogic Systems Inc A process for discriminating between biological states based on hidden patterns from biological data
AU2001291217A1 (en) 2000-09-22 2002-04-02 University Of Aarhus Novel compositions and methods for lymphoma and leukemia
US20020164576A1 (en) 2000-09-22 2002-11-07 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
AU2002241535B2 (en) 2000-11-16 2006-05-18 Ciphergen Biosystems, Inc. Method for analyzing mass spectra
US7113896B2 (en) 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
US7144708B2 (en) 2001-06-25 2006-12-05 The Cleveland Clinic Foundation Markers of blood barrier disruption and methods of using same
US6884591B2 (en) 2001-06-25 2005-04-26 The Cleveland Clinic Foundation Peripheral marker of blood brain barrier permeability
CA2451789C (en) 2001-06-29 2012-03-27 Meso Scale Technologies, Llc. Assay plates, reader systems and methods for luminescence test measurements
WO2003068947A1 (en) 2001-07-30 2003-08-21 Meso Scale Technologies, Llc. Assay electrodes having immobilized lipid/protein layers and methods of making and using the same
CA2457775A1 (en) 2001-08-20 2003-02-27 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof
WO2003022028A2 (en) 2001-09-10 2003-03-20 Meso Scale Technologies, Llc Methods, reagents, kits and apparatus for protein function analysis
CA3081228C (en) 2001-09-10 2022-02-15 Meso Scale Technologies, Llc Assay buffer, compositions containing the same, and methods of using the same
US20070098728A1 (en) 2001-09-24 2007-05-03 Pedersen Finn S Novel compositions and methods in cancer
WO2003048768A2 (en) 2001-12-05 2003-06-12 Sense Proteomic Limited Protein arrays for allelic variants and uses thereof
KR20040081749A (ko) * 2002-01-14 2004-09-22 헨리 포드 헬쓰 시스템 혈관을 형성하고 혈관신생 및 영양 인자를 생성시키는데사용하기 위한 골수 기질 세포로부터의 물질
US20020193950A1 (en) 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
US7036946B1 (en) 2002-09-13 2006-05-02 Rockwell Collins, Inc. LCD backlight with UV light-emitting diodes and planar reactive element
AU2003302340B8 (en) * 2002-12-24 2008-09-11 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
AU2003302263A1 (en) 2002-12-26 2004-07-29 Meso Scale Technologies, Llc. Assay cartridges and methods of using the same
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US7981362B2 (en) 2003-11-04 2011-07-19 Meso Scale Technologies, Llc Modular assay plates, reader systems and methods for test measurements
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
US20140303041A1 (en) 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
ES2367311T3 (es) 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
EP1745149A4 (en) 2004-04-15 2008-08-06 Univ Florida NEURALE PROTEINS AS BIOMARKERS FOR INJURY TO THE NERVOUS SYSTEM AND OTHER NEURAL DISORDERS
WO2005121798A1 (en) 2004-06-03 2005-12-22 Meso Scale Technologies, Llc Methods and apparatuses for conducting assays
WO2006012351A2 (en) 2004-06-25 2006-02-02 Washington University Markers for brain damage
US20060257943A1 (en) 2005-01-25 2006-11-16 Cis Biotech, Inc. Ischemic biomarkers and their use to predict adverse neurological events from surgery
US7884260B2 (en) 2005-06-14 2011-02-08 University Of Chicago Cell-based screen for agents useful for reducing neuronal demyelination or promoting neuronal remyelination
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
WO2007123976A2 (en) 2006-04-18 2007-11-01 The Board Of Trustees Of The Leland Stanford Junior University Antibody profiling for determination of patient responsiveness
WO2007136617A2 (en) 2006-05-18 2007-11-29 Walter Reed Army Institute Of Research (Wrair) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
US8088584B2 (en) 2006-10-16 2012-01-03 Bayer Schering Pharma Aktiengesellschaft LTBP2 as a biomarker and diagnostic target
JP5240945B2 (ja) 2006-11-28 2013-07-17 ピクター リミテッド アッセイ膜およびその使用法
WO2008097618A1 (en) 2007-02-06 2008-08-14 University Of Florida Research Foundation, Inc. Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury
EP2015196A1 (en) 2007-06-28 2009-01-14 Siemens Aktiengesellschaft Programmer interface for manufacturing execution system
JP2011511301A (ja) 2008-02-04 2011-04-07 バンヤン・バイオマーカーズ・インコーポレイテッド 脳損傷を診断または治療するための方法
US8497078B2 (en) 2008-05-23 2013-07-30 The Johns Hopkins University Biomarkers for myocardial ischemia
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
WO2010017515A2 (en) 2008-08-08 2010-02-11 Integrated Diagnostics Inc. Breast cancer specific markers and methods of use
WO2010019553A2 (en) * 2008-08-11 2010-02-18 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US20140342381A1 (en) 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
CA2766057A1 (en) * 2009-06-19 2010-12-23 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
US20170315136A9 (en) 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
AU2010291933B2 (en) 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
GB201008541D0 (en) 2010-05-21 2010-07-07 Univ Geneve Diagnostic methods
WO2012051519A2 (en) * 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
MX2013008746A (es) 2011-01-28 2014-06-23 Immunosciences Lab Inc Metodo para la deteccion de permeabilidad intestinal y de la barrera hemato-encefalica y materiales de prueba para este.
WO2012155134A2 (en) 2011-05-12 2012-11-15 The Johns Hopkins University Assay reagents for a neurogranin diagnostic kit
WO2012170998A1 (en) 2011-06-10 2012-12-13 Cornell University Immobilized protein system for rapid and enhanced multiplexed diagnostics
WO2013173596A1 (en) 2012-05-16 2013-11-21 Trustees Of Boston University Chronic traumatic encephalopathy in blast-exposed individuals
WO2014194329A1 (en) 2013-05-31 2014-12-04 Banyan Biomarkers, Inc. NEURAL SPECIFIC S100β FOR BIOMARKER ASSAYS AND DEVICES FOR DETECTION OF A NEUROLOGICAL CONDITION
EP3022322A4 (en) 2013-07-17 2017-05-17 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
WO2015066211A1 (en) 2013-10-29 2015-05-07 Banyan Biomarkers, Inc. Uch-l1 isoforms, assays and devices for detection of a neurological condition

Also Published As

Publication number Publication date
US20230077876A1 (en) 2023-03-16
WO2015009907A1 (en) 2015-01-22
EP3022322A4 (en) 2017-05-17
IL243393A0 (en) 2016-03-31
EP3757226A2 (en) 2020-12-30
JP2020034567A (ja) 2020-03-05
JP6980291B2 (ja) 2021-12-15
EP3757226A3 (en) 2021-05-05
US20160178643A1 (en) 2016-06-23
US10534003B2 (en) 2020-01-14
US11499982B2 (en) 2022-11-15
US20200116739A1 (en) 2020-04-16
EP3022322A1 (en) 2016-05-25
US12339288B2 (en) 2025-06-24
JP2022023999A (ja) 2022-02-08
JP2016533499A (ja) 2016-10-27

Similar Documents

Publication Publication Date Title
JP6980291B2 (ja) 脳損傷の診断／予後判定／評価において有用な組成物及びキット
US12265091B2 (en) Circulating biomarker levels for diagnosis and risk-stratification of traumatic brain injury
US12461112B2 (en) Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
US20250044303A1 (en) Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
JP6071886B2 (ja) 脳損傷のバイオマーカー
JP2023531521A (ja) 神経損傷および疾患を検出、予後判定、およびモニタリングするためのマルチモダリティシステムおよび方法
US9678086B2 (en) Diagnostic assay for Alzheimer's disease
EP3245520B1 (en) Serum biomarker panels for bipolar disorder
US20140147874A1 (en) Biomarkers of cardiac ischemia
US20250035650A1 (en) Biomarker testing for chronic persistent injury following brain trauma
US20250155455A1 (en) Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
WO2025179300A1 (en) Biomarkers, compositions, kits, and methods distinguishing acute geriatric tbi from pre-existing dementia or cognitive impairment
HK40006969A (en) Histones and/or proadm as markers indicating organ dysfunction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160229

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160229

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170714

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191029

R150 Certificate of patent or registration of utility model

Ref document number: 6611710

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250